These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 24549815

  • 1. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
    Zhang H, Li Z, Wang K.
    Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
    [Abstract] [Full Text] [Related]

  • 2. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M.
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [Abstract] [Full Text] [Related]

  • 3. Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
    Zhang H, Li Z, Wang K, Ren P.
    Oncol Rep; 2015 Mar; 33(3):1079-88. PubMed ID: 25524805
    [Abstract] [Full Text] [Related]

  • 4. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J, Xiu P, Dong X, Wang F, Wei H, Wang X, Xu Z, Liu F, Li T, Wang Y, Li J.
    Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
    [Abstract] [Full Text] [Related]

  • 5. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
    Yang Q, Zhang S, Kang M, Dong R, Zhao J.
    Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
    [Abstract] [Full Text] [Related]

  • 6. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W, Liu S, Liu K, Ji B, Wang Y, Liu Y.
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [Abstract] [Full Text] [Related]

  • 7. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    Chen C, Ju R, Shi J, Chen W, Sun F, Zhu L, Li J, Zhang D, Ye C, Guo L.
    J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
    [Abstract] [Full Text] [Related]

  • 8. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M, Qian D, Jing H, Li Y, Ma C, Zhou Y.
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [Abstract] [Full Text] [Related]

  • 9. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 10. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.
    Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M.
    BMC Cancer; 2013 Jun 03; 13():273. PubMed ID: 23731702
    [Abstract] [Full Text] [Related]

  • 11. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 03; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

  • 12. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
    Fulzele SV, Shaik MS, Chatterjee A, Singh M.
    J Pharm Pharmacol; 2006 Mar 03; 58(3):327-36. PubMed ID: 16536899
    [Abstract] [Full Text] [Related]

  • 13. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.
    Clin Cancer Res; 2010 Oct 15; 16(20):4990-5001. PubMed ID: 20810384
    [Abstract] [Full Text] [Related]

  • 14. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
    Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M.
    Pharm Res; 2006 Sep 15; 23(9):2094-106. PubMed ID: 16902813
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.
    Cancer Lett; 2010 Feb 28; 288(2):251-60. PubMed ID: 19664879
    [Abstract] [Full Text] [Related]

  • 16. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I.
    Am J Clin Oncol; 2003 Aug 28; 26(4):S103-9. PubMed ID: 12902866
    [Abstract] [Full Text] [Related]

  • 17. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 18. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y.
    Biochem Biophys Res Commun; 2015 Dec 25; 468(4):525-32. PubMed ID: 26482853
    [Abstract] [Full Text] [Related]

  • 19. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
    Winters ME, Mehta AI, Petricoin EF, Kohn EC, Liotta LA.
    Cancer Res; 2005 May 01; 65(9):3853-60. PubMed ID: 15867384
    [Abstract] [Full Text] [Related]

  • 20. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
    Giovannetti E, Labots M, Dekker H, Galvani E, Lind JS, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, Peters GJ.
    Curr Pharm Des; 2013 May 01; 19(5):927-39. PubMed ID: 22973961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.